|1.||Maelicke, Alfred: 2 articles (01/2015 - 01/2010)|
|2.||Montag, Dirk: 1 article (01/2015)|
|3.||Bhattacharya, Soumee: 1 article (01/2015)|
|4.||Koepke, Andreas K E: 1 article (01/2010)|
|5.||Hoeffle-Maas, Anja: 1 article (01/2010)|
|6.||Ludwig, Juergen: 1 article (01/2010)|
|7.||Jordis, Ulrich: 1 article (01/2010)|
|8.||Samochocki, Marek: 1 article (01/2010)|
|9.||Maus, Arno: 1 article (01/2010)|
|1.||Alzheimer Disease (Alzheimer's Disease)
01/01/2010 - "Based on these and other preclinical data, Memogain may represent an advantageous drug treatment for Alzheimer's disease, combining much lesser gastrointestinal side effects and considerably higher potency in enhancing cognition, as compared to presently available drugs."
01/01/2015 - "Nasal Application of the Galantamine Pro-drug Memogain Slows Down Plaque Deposition and Ameliorates Behavior in 5X Familial Alzheimer's Disease Mice."
01/01/2015 - "In this study, the 5X Familial Alzheimer's Disease (5XFAD) mouse model was used to investigate the effect of chronic Memogain treatment on behavior and amyloid-β (Aβ) plaque deposition in the brain. "
01/01/2010 - "Memogain (Gln-1062) is an inactive pro-drug of galantamine, the latter being a plant alkaloid approved for the treatment of mild to moderate Alzheimer's disease. "
|2.||Amnesia (Dissociative Amnesia)
01/01/2010 - "In animal models of drug-induced amnesia, Memogain produced several fold larger cognitive improvement than the same doses of galantamine, without exhibiting any significant levels of gastrointestinal side effects that are typical for the unmodified drug and other inhibitors of cholinesterases, such as donepezil and rivastigmin. "
|2.||Amyloid (Amyloid Fibrils)